Historically, the structural and
|
|
- Ophelia McCarthy
- 6 years ago
- Views:
Transcription
1 46 supplement to Journal of the association of physicians of india march 2014 VOL. 62 Montelukast - Place in Therapy Agam C Vora * Historically, the structural and functional differences within the respiratory tract have served as the basis for separating the airway into upper and lower components. As such, asthma and allergic rhinitis have been diagnosed and managed by clinicians as distinct upper and lower airway diseases, respectively. Consistent with this idea of distinct diseases, researchers have developed drugs in years past for specific treatment of either asthma or allergic rhinitis. However, during the past decade, the focus of study has shifted to the role of the arachidonic acid metabolic pathway and other inflammatory mediators in the pathophysiology and treatment of upper and lower airway disease. Recent advances in inflammatory mediators have prompted members of the medical and scientific communities to recognise asthma and allergic rhinitis as being a continuum of inflammation within one common airway. 1 Leukotrienes (LTC 4, LTD 4, LTE 4 ) are important proinflammatory mediators in asthma. They are appropriately named as the leukotrienes are produced by leucocytes and their chemical structure contains three double bonds, a triene. These eicosanoids are derived from the metabolism of membrane phospholipids within alveolar macrophages, eosinophils, mast cells and neutrophils, that are involved in the pathophysiology of this disease. 2 The production of LTs by these cells depends on the selective expression of the enzymes involved in the metabolic pathway. LTA4 may be directly released into the extracellular environment and they are metabolized by other cells (transcellular biosynthesis). This pathway results in LTB4 production by bronchial epithelial cells, despite 5-lipoxygenase enzyme is absent. These eicosanoids bind to cysteinyl leukotriene (CysLT) receptors. CysLTs activate type 1 and type 2 leukotriene receptors (CysLT1 and CysLT2) on cell membranes. CysLT1 receptors are localised primarily on pulmonary smooth muscle cells. Activation of these receptors by CysLT leads to decreased activity of respiratory cilia, increased mucus secretion, increased venopermeability and promotion of eosinophils into the airways. This, in turn, induces airway smooth-muscle proliferation and may play a role in the development of airway remodeling. Moreover, CysLTs are the most potent bronchoconstrictive agents * Asst. Hon. and In Charge - Dept. of Chest and TB, Dr. R. N. Cooper Muni. Gen. Hospital, Mumbai
2 supplement to Journal of the association of physicians of india march 2014 VOL discovered, being times more potent than histamines. The synthesis and release of leukotrienes appear not to be blocked by corticosteroid therapy. 3,4 CysLTs receptor antagonists bind the LTD4 receptor and prevent the interaction between the receptor and its physiological ligands. 5 Due to this receptor obstruction, LTs cannot activate the signal transduction that leads to bronchoconstriction. Among LTRAs, zafirlukast, pranlukast and montelukast have been approved in several countries for asthma treatment of adults and children. Montelukast, is the most specific and powerful LTs receptor antagonist, and is the only LTRA that has been approved for preschool children use in several countries. In addition to its use as controller drug in allergic and viral-induced asthma, it decreases also bronchial hyperreactivity and prevents bronchial obstruction induced by physical activity at preschool and school age. Montelukast binds with high affinity and selectivity to the CysLT1 receptor (in preference to other pharmacologically important airway receptors, such as the prostanoid, cholinergic, or β-adrenergic receptor). Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. 6 It is rapidly absorbed after administration reaching peak plasma concentration (Cmax) in 3 to 4 hours with a mean bioavailability of 64% following a 10 mg oral administration. For the 5 mg chewable tablet, the mean Cmax is achieved in 2 to 2.5 hours with a mean bioavailability of 73% fasting versus 63% with the standard meal. Montelukast is more than 99% bound to plasma proteins with minimal distribution across the blood-brain barrier. Excretion occurs almost exclusively in bile with a half-life from 2.7 to 5.5 hours in healthy adults. The pharmacokinetic profile is similar in females and males, young and elderly. 7 Montelukast in Allergic Rhinitis LTRAs can be considered an established treatment option for asthma, with published clinical evidence for their efficacy and tolerability in this indication dating back to the early 1990s. More recently, evidence has also started to accumulate in support of their utility in the treatment of AR. 8 Monotherapy: A multicentre, double-blind trial involving 450 men and 852 women with spring seasonal allergic rhinitis randomised to once-daily montelukast (10 mg), loratadine (10 mg) or placebo for 2 weeks showed that the change from baseline in daytime nasal symptoms score was significantly (p < 0.001) greater with montelukast and loratadine than with placebo, but that nighttime symptoms were better controlled with montelukast. Peripheral blood eosinophil counts were significantly (p < 0.001) decreased with montelukast but not with loratadine or placebo. 9 A study by Chervinsky et al showed similar improvement of symptoms in patients treated with montelukast in comparison to placebo in an evaluation of the results of three prospective clinical trials in fall AR patients. 10 Combination Therapy: Montelukast traditionally used as anti-inflammatory drugs in the long-term treatment of asthma in adults, adolescents, and school-age children. Now a days its use in allergic rhinitis has gained importance. Furthermore, there are many combinations of montelukast with levocetrizine or desloratidine are in market for the treatment of allergic rhinitis. In one study, a combination of montelukast and loratadine has been found to be superior to either montelukast or loratadine alone in seasonal allergic rhinitis. 11 In patients with persistent AR, the combination of montelukast and either desloratadine or levocetirizine were more effective than monotherapy with either of these three medications. 12 Montelukast in combination with cetirizine showed better control of the clinical nasal symptoms and reduced eosinophil counts better than either montelukast or cetirizine alone in seasonal AR patients. 13 Montelukast in Bronchial Asthma Although LTRAs were considered as first line therapy in the management of mild to moderate persistent asthma since their discovery, a Cochrane review consisting of 13 randomised controlled trials, concluded that low doses of inhaled glucocorticoids were superior to LTRAs. 14 Various current international guidelines (Global Initiative for Asthma, GINA; British Thoracic Society, BTS; National Institute of Health, NIH) recommend the use of low-dose inhaled corticosteroids (ICSs) as the preferred controller therapy, with LTRAs as an alternative, for the management of persistent asthma in children (5 11 years of age) and adolescents. In patients unresponsive to ICSs alone, the alternative options are the addition of LTRAs or long-acting beta-agonist (LABA), or an increase of ICS dosage. Montelukast as Monotherapy Leukotriene receptor antagonists have beneficial clinical effect in all age groups and are proposed in GINA and NAEPP guidelines as an option for monotherapy. Montelukast was found to be effective in mild persistent asthmatics with near normal lung functions. 15 The clinical efficacy of montelukast in adults and children with persistent asthma, including patients sensitive to aspirin, has been evaluated in several randomised, double-blind, placebo controlled trials. Montelukast have demonstrated an important role in aspirin-induced asthma. It has long been known
3 48 supplement to Journal of the association of physicians of india march 2014 VOL. 62 that 5-10% of asthmatics are exquisitely sensitive to aspirin, so that ingestion of even a very small dose causes profound bronchoconstriction and symptoms of systemic release of histamine, such as flushing and abdominal cramping. Because this reaction to aspirin is not associated with any evidence of allergic sensitisation to aspirin or its metabolites and because it is produced by any of the nonsteroidal anti-inflammatory agents, it is thought to result from inhibition of prostaglandin synthetase (cyclooxygenase), shifting arachidonic acid metabolism from the prostaglandin to the leukotriene pathway. Support for this idea was provided by the demonstration that leukotriene pathway inhibitors impressively reduce the response to aspirin challenge and improve overall control of asthma on a day-to-day basis. [16] Lee et al in a study found that a single 10 mg dose of montelukast partially protected against the local effects of nasal lysine-aspirin challenge. 17 In a study on asthmatic patients greater than 15 year age, Reiss et al found that Montelukast improved FEV1, peak expiratory flow rates, daytime asthma symptoms, nocturnal awakening significantly as compared to placebo. Also need of rescue medications (β agonists) was significantly less in patients taking Montelukast as compared to placebo. 18 In another study, Montelukast was associated with significantly better protection against exercise induced asthma as compared to placebo. The maximum decrease in exercise induced FEV1 was significantly improved in patients taking Montelukast as compared to patients taking placebo. 19 Montelukast in combination therapy Various studies have assessed the role of Montelukast in combination therapy with other asthma medications or as an add on therapy to ICS. Montelukast provides improvement symptoms and in lung function, decrease in acute exacerebrations and dose of ICS. Apart from these, many studies have evaluated the role of Montelukast on quality of life of asthma patients and found consistent improvement in QOL with Montelukast as compared to placebo. Blood eosinophil count was found to be decreased during Montelukast treatment in many studies. 20 Montelukast as an add on therapy to ICS improves control in mild to moderate asthma compared to ICS monotherapy with similar safety profile. In active controlled studies, montelukast + ICS was clinically less effective as compared to salmeterol + ICS in most of the 12 weeks trials. However, 48 week trials showed comparable proportion of patients with 1 exacerbation in both the groups. Until recent, there were no comparative studies for ICS + LABA and ICS + LABA + montelukast, which is compared in recently published MONICA study. The MONtelukast In Chronic Asthma (MONICA) study was an open-label study in which add-on montelukast therapy in a real-world setting over 3 and 6 months improved asthma control in patients with mild to moderate persistent asthma who were not sufficiently controlled by ICS or the combination of ICS and LABA. Asthma control was assessed by the Asthma control test (ACT), a short and relatively simple, validated, patient based, five-item questionnaire that is one of the assessment tools for asthma control recommended by GINA. The control of asthma was found to be improved after addition of montelukast as assessed by ACT score. Additionally, clinically meaningful improvement in quality of life of patients were observed after addition of montelukast when the same was assessed using mini-asthma quality of life questionnaire (mini- AQLQ). 21 Montelukast in Patients with Concomitant Allergic Rhinitis and Asthma Individuals with AR are at a 3- to 12-fold greater risk of also having asthma or developing it later in life. These two medical conditions have interacting manifestations of a common underlying etiology. They share pathophysiological features such as early- and late-response components, infiltration of the mucosa by eosinophils, and mediation of key inflammatory events by CysLT. Many studies have evaluated role of montelukast in concomitant asthma and allergic rhinitis. 22 In a study, Busse et al found that montelukast improved asthma symptoms the use of asthma rescue medications. 23 The first demonstrations of the efficacy of montelukast in asthma were obtained in the mid- 1990s, when the results of both comparative studies of montelukast versus placebo and studies of the protective effect of montelukast on bronchoconstriction induced by exercise or other nonspecific stimuli were published. 24 Montelukast improved symptoms, rescue medication use and pulmonary function, and reduced the rate of exacerbation and the level of blood eosinophils, in mild-to moderate asthmatics not treated with ICS. Montelukast also protected against bronchoconstriction induced by exercise better than long acting beta2-agonists (LABAs). 25 These data led to the introduction of montelukast into the market at the end of the 1990s. After the results of montelukast in monotherapy and its potential additive effect to ICS, many studies have been performed in order to assess the efficacy of montelukast as add-on therapy. When added to ICS, montelukast induced further improvement in
4 supplement to Journal of the association of physicians of india march 2014 VOL symptoms and pulmonary function, particularly in patients still symptomatic despite treatment with ICS. 26 Although in short-term studies the combination of ICS plus LABA was more effective on symptoms and pulmonary function than ICS plus montelukast, 27,28 in a 1-year study especially designed to assess efficacy with regard to rate of severe exacerbations, fluticasone plus montelukast provided equivalent clinical control to fluticasone plus salmeterol, and was associated with a greater reduction in blood eosinophilia. 29 A recent systematic review suggests that different conclusions may be drawn when either short term or long-term trials are considered: in 12-week trials, efficacy with regard to rate of exacerbations is higher for salmeterol plus ICS than montelukast plus ICS, with a similar safety profile, whereas in 48-week trials, the two treatments are similar, with a lower rate of adverse events for montelukast plus ICS. 30 Safety and Tolerability of Montelukast Montelukast is well tolerated with a safety profile that is similar in adult and paediatric populations. Studies have demonstrated no clinical or laboratory difference in adverse experiences of montelukast as compared to placebo. 22 Most common adverse effects include headache, gastrointestinal disturbances, fatigue, pharyngitis, upper respiratory tract infection and rash. These adverse events occurred more than 1% that of placebo. Isolated reports of Churg-Strauss syndrome (CSS), a rare systemic vasculitis associated with asthma, have been reported in asthma patients treated with montelukast. The prevalence of CSS is 60 per million asthma patients whereas in general population it affects 2 to 7 people per million. The cause is unknown but it is often preceded by tapering of steroid treatment. The possible explanation for slight higher prevalence of CSS among patients taking montelukast is that, inhaled or oral corticosteroid treatment in these patients may mask the underlying vasculitis that develops as the glucocorticosteroid doses are reduced in patients with severe asthma being treated with leukotriene receptor antagonists (LTRAs). Particular attention should be given to the consideration of periodically monitoring liver function tests during treatment with LTRA. Most recently, the FDA has published reports of agitation, aggression, anxiousness, dream abnormalities, hallucinations, depression, insomnia, irritability, restlessness, suicide, suicidal ideation, and tremor associated with the use of montelukast and other LTRAs based upon post marketing reports published by the drug manufacturer. Conclusion To conclude, montelukast is highly specific CysLT1 receptor antagonist. The efficacy in both AR and asthma is better than placebo. It can be useful as monotherapy in patients with mild persistent asthma with near normal lung functions and for the control in aspirin induced asthma. Montelukast is a suitable option as add on therapy when asthma is not controlled on ICS monotherapy or combination of ICS and LABA. The safety and tolerability is good among patients but a rare possibility of Chrug Strauss syndrome should be kept in mind. References 1. Jay Grossman. One airway one disease. Chest 1997;111:11S-16S 2. Dempsey OJ. Leukotriene receptor antagonist therapy. Postgrad Med J 2000;76: Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341: Jeffrey M Drazen, Elliot Israel, Paul M O Byrne, Treatment of Asthma with Drugs Modifying the Leukotriene Pathway. N Engl J Med 1999;340: Bernstein PR: Chemistry and structure activity relationships of leukotriene receptor antagonists. Am J Respir Crit Care Med 1998;157:s220 s Hakim F, Vilzoni D, Adler A, Livnat G, Tal A, Bentur L: The effect of montelukast on bronchial hyperreactivity in preschool children. Chest 2007;13: Merck & Co WS NJ. Singulair (montelukast sodium). Product information. (Cited 2009 April 20) Available from: wwwsingulaircom/singulair/shared/documents/english/singulair_ prescribing_infopdf G Philip, K Malmstrom, FC Hampel Jr, SF Weinstein, CF LaForce, PH Ratner, MP Malice, TF Reiss. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32: Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, doubleblind trial. Arch Intern Med 1998;158: Chervinsky P, Philip G, Malice MP, et al. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann Allergy Asthma Immunol 2004;92: Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebocontrolled clinical trial. J Allergy Clin Immunol 2000;105: Ciebiada M, Gorska-Ciebiada M, DuBuske LM, et al. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol 2006;97: Kurowski M, Kuna P, Gorski P. Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal alelrgy inflammation. Allergy 2004;58: Ducharme FM, Hicks GC. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. The Cochrane Database of
5 50 supplement to Journal of the association of physicians of india march 2014 VOL. 62 Systematic Reviews (Complete Reviews), Issue. Art. No.: CD DOI: / CD Peter SP, Anthonisen N, Castro M et al. Randomized Comparison of Strategies for Reducing Treatment in Mild Persistent Asthma. N Engl J Med 2007;356: Homer A. Drugs used in Asthma. In: Betram G Katzung, Susan B Masters edotors. Basic and clinical pharmacology. 12 th ed; Tata McGraw Hill Education Pvt Ltd. New Delhi: 2012; D.K.C. Lee, K. Haggart, F.M. Robb, B.J. Lipworth. Montelukast protects against nasal lysine-aspirin challenge in patients with aspirininduced asthma. Eur Respir J 2004;24: Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998;158: Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotrienereceptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339: Jean Bousquet, Pascal Demoly, Marc Humbert. Montelukast in Guidelines and Beyond. Adv Ther 2009;26: J. Christian Virchow, Anish Mehta, Li Ljungblad, Harald Mitfessel. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: The MONtelukast In Chronic Asthma (MONICA) study. Respiratory Medicine 2009;doi: /j. rmed Nayak A, Langdon R. Montelukast in the Treatment of Allergic Rhinitis. Drugs 2007;67: Busse WW, Casale TB, Dykewicz MS, et al. Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. Ann Allergy Asthma Immunol 2006;96: Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of mild asthma and exercise induced bronchoconstriction. New Engl J Med 1998;339: Villaran C, O Neill SJ, Helbling A, van Noord JA, Lee TH, Chuchalin AG, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. J Allergy Clin Immunol 1999;104: Vaquerizo MJ, Casan P, Castillo J, Perpin a, M, Sanchis J, Sobradillo V, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003;58: Deykin A, Wechsler ME, Boushey HA, Chinchilli VM, Kunselman SJ, Craig TJ, et al. Combination therapy with a long-acting beta agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med 2007;175: Fish JE, Israel E, Murray JJ, Emmett A, Boone R, Yancey SW, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001;120: Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening AP, Haahtela T, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: One year, double blind, randomised, comparative trial. BMJ 2003;327: Joos S, Miksch A, Szemcsenyi J, Wieseler B, Grouven U, Kaiser T, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: A systematic review. Thorax 2008;63:
Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma
Allergy 2001: 56: Suppl. 66: 7 11 Printed in UK. All rights reserved Copyright # Munksgaard 2001 ALLERGY ISSN 0108-1675 Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor
More informationMonocast Description Indications
Monocast Tablet Description The active ingredient of Monocast tablet is Montelukast Sodium INN. Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationALLERGIC RHINITIS AND ASTHMA :
ALLERGIC RHINITIS AND ASTHMA : from the Link to Emerging Therapies Allergic rhinitis and asthma are both chronic heterogeneous disorders, with an overlapping epidemiology of prevalence, health care costs
More informationRole of Leukotriene Receptor Antagonists in the Treatment of Exercise-Induced Bronchoconstriction: A Review
Review Article Role of Leukotriene Receptor Antagonists in the Treatment of Exercise-Induced Bronchoconstriction: A Review George S. Philteos, MD, FRCP(C); Beth E. Davis, BSc; Donald W. Cockcroft, MD,
More informationComposition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:
Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved
More informationDrug Use Criteria: Leukotriene Receptor Antagonists
Texas Vendor Drug Program Drug Use Criteria: Leukotriene Receptor Antagonists Publication History Developed February 2007. Revised March 2016; June 2014; October 2012; November 2010; October 2010; September
More informationImpact of Asthma in the U.S. per Year. Asthma Epidemiology and Pathophysiology. Risk Factors for Asthma. Childhood Asthma Costs of Asthma
American Association for Respiratory Care Asthma Educator Certification Prep Course Asthma Epidemiology and Pathophysiology Robert C. Cohn, MD, FAARC MetroHealth Medical Center Cleveland, OH Impact of
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationGuideline topic: Pharmacological management of asthma Evidence table 4.4d: Leukotriene receptor antagonists with short-acting betaagonists
1 of 5 09/05/2018, 11:12 Guideline topic: Pharmacological management of asthma Evidence table 4.4d: Leukotriene receptor antagonists with short-acting betaagonists Author Year Study type Quality rating
More informationLack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children
Eur Respir J 2006; 28: 291 295 DOI: 10.1183/09031936.06.00020606 CopyrightßERS Journals Ltd 2006 Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children
More informationIs reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is reslizumab effective in improving
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationManagement of Bronchial Asthma in Adults..emerging role of anti-leukotriene
Management of Bronchial Asthma in Adults..emerging role of anti-leukotriene Han-Pin Kuo MD, PhD Department of Thoracic Medicine Chang Gung University Chang Gung Memorial Hospital Taipei, Taiwan Bronchial
More informationEfficacy and Safety of Montelukast as Monotherapy in Children with Mild Persistent Asthma. Gautam Ghosh, Arun Kumar Manglik and Subhasis Roy
Efficacy and Safety of Montelukast as Monotherapy in Children with Mild Persistent Asthma Gautam Ghosh, Arun Kumar Manglik and Subhasis Roy From the Shree Jain Hospital & Research Center, Howrah 711 102
More informationEvidence-based recommendations or Show me the patients selected and I will tell you the results
Respiratory Medicine (2006) 100, S17 S21 Evidence-based recommendations or Show me the patients selected and I will tell you the results Leif Bjermer Department of Respiratory Medicine & Allergology, 221
More informationEfficacy of Levocetirizine Compared with Montelukast for the Treatment of Allergic Rhinitis
Human Journals Research Article July 2018 Vol.:10, Issue:1 All rights are reserved by Manju K Mathew et al. Efficacy of Levocetirizine Compared with Montelukast for the Treatment of Allergic Rhinitis Keywords:
More informationAntileukotrienes and asthma: Alternative or adjunct to inhaled steroids?
CURRENT DRUG THERAPY MANI S. KAVURU, MD Director, Pulmonary Function Laboratory, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic REVATHI SUBRAMONY, RPH Staff Pharmacist, Metrohealth
More informationDual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.
DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationMontelukast: its role in the treatment of childhood asthma
REVIEW Montelukast: its role in the treatment of childhood asthma Koray Harmanci Department of Allergy, Ministry of Health, Ankara Diskapi Children s Diseases Training and Research Hospital, Ankara, Turkey
More informationMontelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections
Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections Barbara Knorr, MD, a Sherry Holland, PhD, b J. Douglas Rogers, PhD, c Ha H. Nguyen, PhD, d and Theodore
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationALLERGIC RHINOSINUSITIS. Sirisha A Post graduate Dept of Pharmacology Kamineni Institute of Medical Sciences
ALLERGIC RHINOSINUSITIS Sirisha A Post graduate Dept of Pharmacology Kamineni Institute of Medical Sciences OVERVIEW Pathophysiology Goals of therapy Approaches to therapy Antihistaminics Corticosteroids
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationMTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride
MTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride COMPOSITION MTnL Tablets Each film-coated tablet contains: Montelukast sodium equivalent to montelukast Levocetirizine dihydrochloride
More informationEfficacy and safety of montelukast in adults with asthma and allergic rhinitis
Respiratory Medicine (26), 1952 1959 Efficacy and safety of montelukast in adults with asthma and allergic rhinitis J.Chr. Virchow a,, C. Bachert b a Universität Rostock, Ernst-Heydemann-Str. 6, 1857 Rostock,
More informationThe recent guidelines from the
...PRESENTATIONS... Adjunctive Therapy for Asthma: Treatment Options Robert A. Nathan, MD Abstract The National Heart, Lung, and Blood Institute guidelines on the diagnosis and management of asthma recommend
More informationInternational Journal of Medical Science and Education pissn eissn
COMPARISON OF MONTELUKAST AND KETOTIFEN AS ADD ON THERAPY IN MODERATE AND SEVERE PERSISTENT BRONCHIAL ASTHMA Dr. Gaurav Chhabra 1, Dr. Shubhakaran Sharma 2* Original research article 1,2 Associate professor,
More informationBritish Journal of Clinical Pharmacology
et al. et al. British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2004.02072.x Effects of single or combined histamine H 1 -receptor and leukotriene CysLT 1 -receptor antagonism on nasal adenosine
More informationMontelukast: a better alternative than antihistaminics in allergic rhinitis
International Journal of Otorhinolaryngology and Head and Neck Surgery Kaur G et al. Int J Otorhinolaryngol Head Neck Surg. 017 Apr;():17- http://www.ijorl.com pissn -99 eissn -97 Original Research Article
More informationImmunology of Asthma. Kenneth J. Goodrum,Ph. Ph.D. Ohio University College of Osteopathic Medicine
Immunology of Asthma Kenneth J. Goodrum,Ph Ph.D. Ohio University College of Osteopathic Medicine Outline! Consensus characteristics! Allergens:role in asthma! Immune/inflammatory basis! Genetic basis!
More informationMANAGEMENT OF ASTHMA WITH MONTELUKAST
MANAGEMENT OF ASTHMA WITH MONTELUKAST Nipun Shrestha and Hongzhu Lu * Department of Pediatrics, Clinical Medical College, Yangtze University. Jingzhou, Hubei, P.R.China. ABSTRACT Respiratory tract disorder
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationMeeting the Challenges of Asthma
Presenter Disclosure Information 11:05 11:45am Meeting the Challenge of Asthma SPEAKER Christopher Fanta, MD The following relationships exist related to this presentation: Christopher Fanta, MD: No financial
More informationAsthma is characterized by airway hyperresponsiveness
Long-Acting Bronchodilator or Leukotriene Modifier as Add-on Therapy to Inhaled Corticosteroids in Persistent Asthma?* Graeme P. Currie, MD; Daniel K. C. Lee, MD; and Prasima Srivastava, MD Despite the
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More informationViral-Induced Asthma:
Viral-Induced : Sorting through the Studies Malcolm R. Sears, MB, FRACP, FRCPC Presented at the Respirology Update Continuing Education Program, January 2005 Viral-associated wheezing is common and not
More informationEIB in adults and children
Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast David S. Pearlman, MD*; Janet van Adelsberg, MD ; George Philip, MD ; Stephen A. Tilles,
More informationRespiratory Pharmacology
Allergy Targets of allergies Type I Histamine Leukotrienes Prostaglandins Bradykinin Hypersensitivity reactions Asthma Characterised by Triggered by Intrinsic Extrinsic (allergic) Mediators Result Early
More informationJames P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD
Therapeutic Effect of Zafirlukast as Monotherapy in Steroid-Naive Patients With Severe Persistent Asthma* James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren,
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More informationAir Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.
Asthma Air Flow Limitation In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. True whether reversible, asthma and exercise-induced bronchospasm,
More informationImmunomodulators: Anti-IgE mab. Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE
Immunomodulators: Anti-IgE mab Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE Objectives To explain the rationale behind IgE blockade To discuss which
More informationMontelukast in the treatment of asthma and beyond
For reprint orders, please contact reprints@expert-reviews.com Montelukast in the treatment of asthma and beyond Expert Rev. Clin. Immunol. 5(6), 639 658 (2009) Zuzana Diamant, Eva Mantzouranis and Leif
More informationSupplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus
Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationAsthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?
10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher
More informationAddition to inhaled corticosteroids of long-acting beta2- agonists versus anti-leukotrienes for chronic asthma (Review)
Addition to inhaled corticosteroids of long-acting beta2- agonists versus anti-leukotrienes for chronic asthma (Review) Ducharme FM, Lasserson TJ, Cates CJ This is a reprint of a Cochrane review, prepared
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Omalizumab Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 6 References... 7 Effective Date... 3/15/2018 Next
More informationManagement of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier
Management of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier Department of Pediatrics, Division of Allergy and Pulmonary Medicine, Washington
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationPredicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa
Predicting, Preventing and Managing Asthma Exacerbations Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Asthma exacerbations Predicting exacerbation recognising
More informationLeukotriene C 4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma
Blackwell Science, LtdOxford, UKBCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Publishing 2003? 2003564422426Original ArticleLeukotriene C4 synthasej. J. Lima et al. Leukotriene C 4 synthase
More informationTrust the Original to help you turn it off.
Trust the Original to help you turn it off. Trust the Original to help you turn it off. Trust the Original to help you turn it off. Trust the Original to help you turn it off. Trust the Original to help
More informationQ: Should patients with mild asthma
1-MINUTE CONSULT CME CREDIT EDUCATIONAL OBJECTIVE: Readers will consider prescribing inhaled corticosteroids to their patients who have mild persistent asthma brief answers to specific clinical questions
More informationPediatric Pharmacotherapy
Pediatric Pharmacotherapy A Monthly Review for Health Care Professionals of the Children's Medical Center Volume 4 Number 10, October 1998 Montelukast: a selective leukotriene receptor antagonist Introduction
More informationAvailable online at
Available online at www.annclinlabsci.org 285 Tapering Dose of Inhaled Budesonide in Subjects with Mild-to-Moderate Persistent Asthma Treated with Montelukast: A 16-Week Single-Blind Randomized Study Graziano
More informationAsthma for Primary Care: Assessment, Control, and Long-Term Management
Asthma for Primary Care: Assessment, Control, and Long-Term Management Learning Objectives After participating in this educational activity, participants should be better able to: 1. Choose the optimal
More informationAlthough elucidation of the basic physiologic
Salmeterol Powder Provides Significantly Better Benefit Than Montelukast in Asthmatic Patients Receiving Concomitant Inhaled Corticosteroid Therapy* James E. Fish, MD, FCCP; Elliot Israel, MD, FCCP; John
More informationMontelukast vs. Inhaled Low-Dose Budesonide as Monotherapy in the Treatment of Mild Persistent Asthma: A Randomized Double Blind Controlled Trial
Montelukast vs. Inhaled Low-Dose Budesonide as Monotherapy in the Treatment of Mild Persistent Asthma: A Randomized Double Blind Controlled Trial by Vikram Kumar, a P. Ramesh, a Rakesh Lodha, a R. M. Pandey,
More informationE-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling
E-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling Ruby Pawankar, MD, Ph.D. FRCP, FAAAAI Prof. Div of Allergy, Dept of Pediatrics Nippon Medical School Tokyo, Japan pawankar.ruby@gmail.com
More informationPharmacy Management Drug Policy
SUBJECT: : Nucala (mepolizumab), Cinqair (reslizumab), & Fasenra (benralizumab) POLICY NUMBER: Pharmacy-62 EFFECTIVE DATE: 12/15 LAST REVIEW DATE: 3/5/2018 If the member s subscriber contract excludes
More informationTherapeutic Effect of Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, on Japanese Patients with Seasonal Allergic Rhinitis
Allergology International. 2008;57:247-255 DOI: 10.2332allergolint.O-07-515 ORIGINAL ARTICLE Therapeutic Effect of Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, on Japanese Patients with
More informationPRODUCT INFORMATION LUKAIR. (montelukast sodium) Tablets NAME OF THE MEDICINE
PRODUCT INFORMATION LUKAIR (montelukast sodium) Tablets NAME OF THE MEDICINE Montelukast sodium LUKAIR, (montelukast sodium) is described chemically as [R-(E)]-1-[[[1-[3-[2-(7-chloro-2- quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]
More informationLeukotriene receptor antagonist therapy
Postgrad Med J 2000;76:767 773 767 Asthma and Allergy Research Group, Department of Clinical Pharmacology and Therapeutics, inewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK
More informationThe ability of peak flow measurement
Lessons Learned From the Asthma Clinical Research Network By Brian Piazza, MS 2 and Timothy J. Craig, DO In 1993, the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health
More informationORIGINAL ARTICLE. Kimihiro Okubo 1 and Kohtaro Baba 2 INTRODUCTION
Allergology International. 2008;57:383-390 DOI: 10.2332allergolint.O-08-533 ORIGINAL ARTICLE A Double-Blind Non-inferiority Clinical Study of Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist,
More informationBronchial Thermoplasty For Severe Persistent Asthma
Bronchial Thermoplasty For Severe Persistent Asthma Faisal Khan MD Center For Respiratory and Sleep Medicine Indiana Internal Medicine Consultants Franciscan Saint Francis hospital Agenda Burden of Severe
More informationBrand Name: Daliresp. Generic Name: roflumilast. Manufacturer: Forest Pharmaceuticals, Inc.
Brand Name: Daliresp Generic Name: roflumilast 3, 4, 5 Manufacturer: Forest Pharmaceuticals, Inc. 1, 2,4,5,7 Drug Class: Second Generation Phosphodiesterase 4 (PDE 4) inhibitor Labeled Uses: prophylaxis
More informationDistinction and Overlap. Allergy Dpt, 2 nd Pediatric Clinic, University of Athens
Asthma Phenotypes: Distinction and Overlap Nikos Papadopoulos Allergy Dpt, 2 nd Pediatric Clinic, University of Athens Asthma as a syndrome From the Iliad to ADAM 33 and back again Bronchoconstriction,
More informationTreating asthma: is there a place for leukotriene receptor antagonists?
Respiratory Medicine (2005) 99, 655 662 Treating asthma: is there a place for leukotriene receptor antagonists? Zuzana Diamant a,, Thys van der Molen b,c a Centre for Human Drug Research, Zernikedreef
More informationCLINICAL PRACTICE. Clinical Practice. N Engl J Med, Vol. 345, No. 17 October 25,
CLINICAL PRACTICE Clinical Practice This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review
More informationPRODUCT INFORMATION SINGULAIR. (montelukast sodium) Tablets and Oral Granules NAME OF THE MEDICINE
PRODUCT INFORMATION SINGULAIR (montelukast sodium) Tablets and Oral Granules NAME OF THE MEDICINE Montelukast sodium SINGULAIR, (montelukast sodium) is described chemically as [R-(E)]-1-[[[1-[3-[2-(7-
More informationBreakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom
Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom 2 BEYOND SYMPTOMS ADDRESSING FUTURE RISK IN ASTHMA South GP CME 2013,
More information31 - Respiratory System
31 - Respiratory System Asthma 1. Asthma has two components. Name the two components. 2. What are the common triggers of asthma? (LP p319) (e.g., pets) Upper respiratory infections ( ) 3. Describe a normal
More informationIndacaterol. Powder capsule administered by a Breezhaler (Onbrez ) or Neohaler (Acapta ) Mechanism of Action Ultra Long-acting beta-2 agonist (LABA)
Indacaterol Powder capsule administered by a Breezhaler (Onbrez ) or Neohaler (Acapta ) Mechanism of Action Ultra Long-acting beta-2 agonist (LABA) Clinical Application Indications: The long-term maintenance
More informationThe proposal is to add text/statements in red and to delete text/statements with strikethrough: POLICY
Omalizumab DESCRIPTION Omalizumab is a recombinant DNA-derived humanized IgG1κ monoclonal antibody which selectively binds to immunoglobulin E (IgE). High serum levels of IgE are found in individuals with
More informationPolicy Effective 4/1/2018
Corporate Medical Policy Interleukin-5 Antagonists Notification File Name: Origination: Last CAP Review: Next CAP Review: Last Review: interleukin_5_antagonists 2/2016 11/2017 11/2018 2/2018 Policy Effective
More informationImmunology of Asthma. Kenneth J. Goodrum,Ph. Ph.D. Ohio University College of Osteopathic Medicine
Immunology of Asthma Kenneth J. Goodrum,Ph Ph.D. Ohio University College of Osteopathic Medicine Outline Consensus characteristics/incidence data Immune/inflammatory basis Etiology/Genetic basis Hygiene
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationPharmacology of drugs used in bronchial asthma & COPD
Pharmacology of drugs used in bronchial asthma & COPD By Prof. Hanan Hagar Pharmacology Unit King Saud University ILOs: The students should be able to 1. Different types of drugs used for treatment of
More informationFDA Briefing Document Nonprescription Drugs Advisory Committee Meeting
FDA Briefing Document Nonprescription Drugs Advisory Committee Meeting Montelukast (Singulair Allergy) NDA 204804 Proposed Indication: Temporarily relieves these symptoms due to hay fever or other upper
More informationHCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview
HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationNew Zealand Data Sheet
New Zealand Data Sheet Name of Medicine SINGULAIR montelukast sodium 10 mg tablet 5 mg chewable tablet 4 mg chewable tablet Presentation 10 mg tablet: A beige rounded square film-coated tablet engraved
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 03/03/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Xolair (omalizumab) Commercial HMO/PPO/CDHP HMO/PPO/CDHP: Rx
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Interleukin (IL)-5 Antagonists: Mepolizumab and Reslizumab Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5
More informationTitle: Leukotriene Receptor Antagonist (LTRA) for Asthma. Date: April 12, 2007
Title: Leukotriene Receptor Antagonist (LTRA) for Asthma Date: April 12, 2007 Context and policy issues: Asthma is a chronic airways condition with symptoms varying from person to person and episode to
More informationControversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
More informationThe Cochrane Database of Systematic Reviews The Cochrane Library, Copyright 2004, The Cochrane Collaboration
Página 1 de 159 The Cochrane Database of Systematic Reviews The Cochrane Library, Copyright 2004, The Cochrane Collaboration Volume (4) 2004 [no page #] Addition of anti-leukotriene agents to inhaled corticosteroids
More informationPreschool Asthma What you need to know in 10 minutes
Preschool Asthma What you need to know in 10 minutes Alan Kaplan MD CCFP(EM) FCFP Family Physician Airways Group of Canada Respiratory Medicine section CFPC Faculty/Presenter Disclosure Faculty: Alan Kaplan
More informationTherapeutic modulation of allergic airways disease with leukotriene receptor antagonists
Q J Med 2005; 98:171 182 doi:10.1093/qjmed/hci024 Review Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists G.P. CURRIE, P. SRIVASTAVA, O.J. DEMPSEY and D.K.C. LEE
More information